18F-florbetaben Aβ imaging in mild cognitive impairment

Table 1 Demographics

				MCI subtype
	HC ( n = 15)	AD ( n = 15)	All MCI ( n = 45)	naMCI ( n = 4)	asMCI ( n = 12)	amMCI ( n = 29)
Age	68.8 ± 6.5	69.5 ± 9.7	72.7 ± 6.5	74.5 ± 6.8	70.2 ± 6.9	73.5 ± 6.3
Years of education	13.3 ± 3.6	12.8 ± 3.9	13.6 ± 3.6	14.8 ± 1.7	15.2 ± 3.9	12.8 ± 3.6
Males, n (%)	8 (53)	10 (66.7)	29 (64)	4 (100)	7 (58)	18 (62)
MMSE	29.5 ± 0.8	23.7 ± 3.8	27.2 ± 1.8^AB	27.3 ± 1.3^AB	27.4 ± 2.2^AB	27.2 ± 1.7^AB
CDR	0.0 ± 0.0	1.0 ± 0.0	0.4 ± 0.2^AB	0.4 ± 0.3^AB	0.5 ± 0.1^AB	0.4 ± 0.2^AB
CDR SOB	0.0 ± 0.0	4.8 ± 1.1	1.5 ± 1.0^AB	1.8 ± 1.0^AB	1.5 ± 1.1^AB	1.5 ± 0.9^AB
Composite EM	0.0 ± 0.8	-3.5 ± 0.8	-2.1 ± 1.1^AB	-0.6 ± 0.4^ABC	-2.3 ± 1.1^AB	-2.2 ± 1.1^AB
Composite NM	0.6 ± 1.1	-3.1 ± 1.8	-0.9 ± 0.9^AB	-0.8 ± 1.0^AB	-0.1 ± 0.4^ABD	-1.3 ± 0.8^AB

AD, Alzheimer's disease; amMCI, amnestic multidomain mild cognitive impairment; asMCI, amnestic single-domain mild cognitive impairment; CDR, Clinical Dementia Rating; EM, episodic memory z score; HC, healthy older controls; MCI, mild cognitive impairment; naMCI, nonamnestic mild cognitive impairment; NM, nonmemory z score; SOB, sum of boxes. ^AP < 0.05, MCI subtype compared with HC. ^BP < 0.05, MCI subtype compared with AD. ^CP < 0.05, naMCI compared with asMCI and amMCI. ^DP < 0.05, asMCI compared with naMCI and amMCI.

ISSN: 1758-9193